201 related articles for article (PubMed ID: 15646829)
1. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening.
Roupa Z; Faros E; Raftopoulos V; Tzavelas G; Kotrotsiou E; Sotiropoulou P; Karanikola E; Skifta E; Ardavanis A
In Vivo; 2004; 18(6):831-6. PubMed ID: 15646829
[TBL] [Abstract][Full Text] [Related]
2. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.
Hensley ML; Robson ME; Kauff ND; Korytowsky B; Castiel M; Ostroff J; Hurley K; Hann LE; Colon J; Spriggs D
Gynecol Oncol; 2003 Jun; 89(3):440-6. PubMed ID: 12798709
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women.
Kurjak A; Prka M; Arenas JM; Sparac V; Merce LT; Corusic A; Ivancic-Kosuta M
Croat Med J; 2005 Oct; 46(5):757-64. PubMed ID: 16158468
[TBL] [Abstract][Full Text] [Related]
4. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study.
Bosse K; Rhiem K; Wappenschmidt B; Hellmich M; Madeja M; Ortmann M; Mallmann P; Schmutzler R
Gynecol Oncol; 2006 Dec; 103(3):1077-82. PubMed ID: 16904167
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.
Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T; Oi H
Gynecol Obstet Invest; 2008; 65(2):133-8. PubMed ID: 17957102
[TBL] [Abstract][Full Text] [Related]
6. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center.
Muto MG; Cramer DW; Brown DL; Welch WR; Harlow BL; Xu H; Brucks JP; Tsao SW; Berkowitz RS
Gynecol Oncol; 1993 Oct; 51(1):12-20. PubMed ID: 8244166
[TBL] [Abstract][Full Text] [Related]
7. [Program for early detection of ovarian cancer for women as prophylaxis provided at a municipal hospital].
Cnota W; Sodowski K; Olesiak-Andryszczak M; Pilch-Kowalczyk M
Wiad Lek; 2004; 57 Suppl 1():43-7. PubMed ID: 15884203
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer screening in women with a family history of breast or ovarian cancer.
Lacey JV; Greene MH; Buys SS; Reding D; Riley TL; Berg CD; Fagerstrom RM; Hartge P
Obstet Gynecol; 2006 Nov; 108(5):1176-84. PubMed ID: 17077240
[TBL] [Abstract][Full Text] [Related]
9. Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women.
Strigini FA; Gadducci A; Del Bravo B; Ferdeghini M; Genazzani AR
Gynecol Oncol; 1996 Apr; 61(1):68-72. PubMed ID: 8626120
[TBL] [Abstract][Full Text] [Related]
10. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
[TBL] [Abstract][Full Text] [Related]
11. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S;
Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524
[TBL] [Abstract][Full Text] [Related]
12. [Association of ovarian tumors with CA-125].
Martínez-Acosta JE; Olguín-Cruces VA
Rev Med Inst Mex Seguro Soc; 2016; 54 Suppl 3():S230-S237. PubMed ID: 27855043
[TBL] [Abstract][Full Text] [Related]
13. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
14. Screening for ovarian cancer.
Quinn MA
Aust Fam Physician; 2001 Jun; 30(6):530-4. PubMed ID: 11458578
[TBL] [Abstract][Full Text] [Related]
15. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
[TBL] [Abstract][Full Text] [Related]
16. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.
Kramer BS; Gohagan J; Prorok PC; Smart C
Cancer; 1993 Jan; 71(2 Suppl):589-93. PubMed ID: 8420681
[TBL] [Abstract][Full Text] [Related]
17. Preoperative assessment of ovarian tumors by CA 125 measurement and transvaginal color Doppler ultrasound.
Kupesić S; Vujisić S; Kurjak A; Mihaljević D; Radosević S
Acta Med Croatica; 2002; 56(1):3-10. PubMed ID: 12455447
[TBL] [Abstract][Full Text] [Related]
18. [Predictive value of CA 125 in detection of ovarian cancer in pre- and postmenopausal patients].
Grzybowski W; Beta J; Fritz A; Durczyński A; Bidziński M; Grabiec M; Jakimiuk AJ
Ginekol Pol; 2010 Jul; 81(7):511-5. PubMed ID: 20825052
[TBL] [Abstract][Full Text] [Related]
19. [Is it possible to have organized screening for ovarian cancer?].
Navone R; Montanari G
Pathologica; 2003 Apr; 95(2):67-70. PubMed ID: 12768874
[No Abstract] [Full Text] [Related]
20. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.
van Nagell JR; DePriest PD; Reedy MB; Gallion HH; Ueland FR; Pavlik EJ; Kryscio RJ
Gynecol Oncol; 2000 Jun; 77(3):350-6. PubMed ID: 10831341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
